Spiracur’s SNaP System’s design eliminates the electric or battery powered pump used to deliver negative pressure wound therapy (NPWT).
The device is indicated for removal of small amounts of exudates from chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic and pressure), surgically closed incisions, flaps and grafts.
Spiracur president and CEO Gary Restani said the Canadian marketplace offers Spiracur an opportunity to expand the presence of SNaP System to patients who benefit from a new device that improves their quality of life.
